Seer, Inc. reported a total revenue of $16.6 million for the fiscal year ending December 31, 2025, marking a 17% increase from $14.2 million in the previous year. This growth was primarily driven by a 29% rise in product sales, which reached $11.2 million, and a 40% increase in service revenue, totaling $4.2 million. However, the company continues to face significant financial challenges, posting a net loss of $73.6 million, a 15% improvement from the $86.6 million loss recorded in 2024. The accumulated deficit as of December 31, 2025, stood at $466 million.
In terms of operational developments, Seer has expanded its customer base to over 190 clients across more than 20 countries since the launch of its Proteograph Product Suite in 2021. The company has also made strides in product innovation, launching the Proteograph ONE assay and SP200 automation instrument in May 2025, which significantly enhanced throughput and data generation capabilities. The Proteograph Product Suite is designed to provide researchers with deep, unbiased access to the proteome, facilitating large-scale biological studies.
Seer’s strategic focus includes increasing the utilization of its installed base and expanding its market presence, particularly in international markets. The company reported a 65% increase in its installed base compared to the previous year, with ongoing efforts to drive higher consumable sales from existing customers. The Proteograph is increasingly being adopted not only by proteomics researchers but also by genomics-focused researchers, bridging the gap between genetic variation and biological function.
Despite these advancements, Seer continues to face challenges, including a reliance on a limited number of customers for revenue and ongoing losses. The company’s cash and cash equivalents totaled $240.6 million as of December 31, 2025, which management believes will be sufficient to support operations for at least the next twelve months. However, the need for additional capital may arise if cash flows from operations do not meet expectations. Looking ahead, Seer aims to solidify its position in the proteomics market and leverage its technology to support the next generation of data-driven biology and precision medicine.
About Seer, Inc.
Seer, Inc. develops innovative proteomics solutions leveraging engineered nanoparticle technology to enable deep, unbiased, large-scale analysis of the proteome. Its Proteograph Product Suite includes consumables, automation, and software for rapid, high-throughput peptide-level proteomic profiling across diverse biofluids and species. The company's platform supports biomarker discovery, proteogenomics, translational research, and clinical applications, advancing precision medicine and biological understanding through scalable, reproducible, and comprehensive proteomic data.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.